Hansoh Pharmaceutical (HKG:3692) said its Aumolertinib Mesylate Tablets has been approved in the European Union as monotherapy for certain forms of advanced non-small cell lung cancer, according to a Friday Hong Kong bourse filing.

The approval covers first-line treatment of adult patients with advanced non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as well as treatment of adult patients with advanced EGFR T790M mutation-positive NSCLC, the filing said.